MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer

International Journal of Cancer

Volumn 134, Issue 10, 2014, Pages 2424-2436

  Kim, Yu Jin ^a   Choi, Jong Sun ^b   Seo, Jinwon ^c   Song, Ji Young ^a   Eun Lee, Seung ^d   Kwon, Mi Jung ^c   Kwon, Mi Jeong ^e   Kundu, Juthika ^f   Jung, Kyungsoo ^a,g   Oh, Ensel ^a,g   Shin, Young Kee ^h   Choi, Yoon La ^a,d,g  

^a Samsung Medical Center   (South Korea)

^b Dongguk University Ilsan Hospital   (South Korea)

^c Hallym University Sacred Heart Hospital   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Kyungpook National University   (South Korea)

^f Keimyung University   (South Korea)

^g Sungkyunkwan University   (South Korea)

^h Seoul National University   (South Korea)

Author keywords

basal like; breast cancer; epidermal growth factor receptor; MET; triple negative

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INDOLES; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS, BASAL CELL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SULFONES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84895928257     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28566     Document Type: Article

References (45)

1. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47.
2. Kaufmann M, Pusztai L,. Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an International Expert Panel. Cancer 2011; 117: 1575-82.
3. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-48.
4. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.
5. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
6. Gastaldi S, Comoglio PM, Trusolino L,. The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res 2010; 12: 208.
7. Trusolino L, Bertotti A, Comoglio PM,. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-48.
8. Comoglio PM, Giordano S, Trusolino L,. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-16.
9. Soman NR, Correa P, Ruiz BA, et al. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci USA 1991; 88: 4892-6.
10. Hara T, Ooi A, Kobayashi M, et al. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998; 78: 1143-53.
11. Miller CT, Lin L, Casper AM, et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006; 25: 409-18.
12. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-7.
13. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
14. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999; 59: 307-10.
15. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19: 4947-53.
16. Chen BK, Ohtsuki Y, Furihata M, et al. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. Pathol Res Pract 1999; 195: 427-33.
17. Di Renzo MF, Olivero M, Katsaros D, et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 1994; 58: 658-62.
18. Tuck AB, Park M, Sterns EE, et al. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996; 148: 225-32.
19. Ferracini R, Olivero M, Di Renzo MF, et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 1996; 12: 1697-705.
20. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, et al. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003; 97: 1841-8.
21. Raghav KP, Wang W, Liu S, et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 2012; 18: 2269-77.
22. Nakopoulou L, Gakiopoulou H, Keramopoulos A, et al. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 2000; 36: 313-25.
23. Ponzo MG, Lesurf R, Petkiewicz S, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009; 106: 12903-8.
24. Graveel CR, DeGroot JD, Su Y, et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009; 106: 12909-14.
25. Gastaldi S, Sassi F, Accornero P, et al. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene 2013; 32: 1428-40.
26. Choi YL, Oh E, Park S, et al. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer 2010; 10: 507.
27. Chou TC,. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976; 59: 253-76.
28. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
29. Chou TC, Motzer RJ, Tong Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.
30. Liu X, Ory V, Chapman S, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012; 180: 599-607.
31. Shattuck DL, Miller JK, Carraway KL, III, et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008; 68: 1471-7.
32. Mueller KL, Hunter LA, Ethier SP, et al. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008; 68: 3314-22.
33. Hochgrafe F, Zhang L, O'Toole SA, et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 2010; 70: 9391-401.
34. Carracedo A, Egervari K, Salido M, et al. FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Res 2009; 11: 402.
35. Zagouri F, Bago-Horvath Z, Rossler F, et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013; 108: 1100-5.
36. Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005; 113: 678-82.
37. Kang JY, Dolled-Filhart M, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63: 1101-5.
38. Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25: 2273-84.
39. Bellusci S, Moens G, Gaudino G, et al. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 1994; 9: 1091-9.
40. Jeffers M, Rong S, Anver M, et al. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. Oncogene 1996; 13: 853-6.
41. Engelman JA,. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin Cancer Res 2007; 13: s4637-40.
42. Mueller KL, Yang ZQ, Haddad R, et al. EGFR/Met association regulates EGFR TKI resistance in breast cancer. J Mol Signal 2010; 5: 8.
43. Agarwal S, Zerillo C, Kolmakova J, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 2009; 100: 941-9.
44. Qi J, McTigue MA, Rogers A, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011; 71: 1081-91.
45. Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010; 70: 6880-90.